Damora Therapeutics (DMRA) Total Assets by Year
Damora Therapeutics, Inc. closed fiscal year 2025 with $260.5M in total assets, $20.1M in total liabilities and $239.0M in shareholder equity. Total assets rose 1420.7% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Damora Therapeutics, Inc. has filed alongside them.
Ticker history: GLTO became DMRA (Damora Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View GLTO history.
Annual figures, oldest first. Point at a bar to read its period.
DMRA Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $260.5M+1420.7% | $17.1M-55.2% | $38.2M-47.8% | $73.2M-40.1% | $122.2M-28.8% | $171.6M+203.1% | $56.6M |
| Total Liabilities | $20.1M+1448.6% | $1.3M-77.9% | $5.9M-48.4% | $11.4M+129.1% | $5.0M-18.3% | $6.1M-95.2% | $127.8M |
| Total Equity | $239.0M+1551.8% | $14.5M-55.2% | $32.3M-47.6% | $61.8M-47.3% | $117.2M-29.2% | $165.5Mn/m | -$71.1M |
DMRA Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $532.6M+4861.1% | $543.6M+3870.8% | $535.4M+3384.8% | $260.5M+1420.7% | $10.7M-54.1% | $13.7M-49.8% | $15.4M-52.7% | $17.1M-55.2% | $23.4M-53.3% | $27.3M-53.6% | $32.5M-49.7% | $38.2M-47.8% |
| Total Liabilities | $36.9M+1250.9% | $27.6M+907.2% | $23.8M+1339.6% | $20.1M+1448.6% | $2.7M+11.8% | $2.7M-26.2% | $1.7M-61.6% | $1.3M-77.9% | $2.4M-80.7% | $3.7M-75.4% | $4.3M-69.8% | $5.9M-48.4% |
| Total Equity | $495.8M+7337.2% | $516.1M+5268.9% | $511.6M+3631.9% | $239.0M+1551.8% | $6.7M-68.2% | $9.6M-59.3% | $13.7M-51.3% | $14.5M-55.2% | $20.9M-44.0% | $23.6M-46.0% | $28.2M-44.1% | $32.3M-47.6% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Damora Therapeutics, Inc. financials
Frequently Asked Questions
Damora Therapeutics, Inc. closed fiscal year 2025 with $260.5M in total assets, $20.1M in total liabilities and $239.0M in shareholder equity.
Damora Therapeutics, Inc. (DMRA) total assets rose by 1420.7% year over year, from $17.1M to $260.5M in fiscal year 2025.
Across the 7 fiscal years this page covers, Damora Therapeutics, Inc. (DMRA) total assets went from $56.6M in fiscal year 2019 to $260.5M in fiscal year 2025.
Damora Therapeutics, Inc. (DMRA) reported $532.6M in total assets in Q3 2026. This represents an increase of 4861.1% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Damora Therapeutics, Inc. (DMRA) reported on that line in every period on record.